| Overview |
| bs-11590R-Cy3 |
| LRP5L Polyclonal Antibody, Cy3 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Sheep, Chicken |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human LRP5L |
| 101-200/252 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm, Nucleus |
| Low-density lipoprotein receptor-related protein 5-like protein; LRP-5-like; LRP5L; GP330; LRP5L_HUMAN. |
| Members of the LDL receptor gene family, including LDLR (low density lipo-protein receptor), LRPs (low density lipoprotein related proteins), Megalin (also designated GP330), VLDLR (very low density lipoprotein receptor) and ApoER2, are characterized by a cluster of cysteine-rich class A repeats, epidermal growth factor (EGF)-like repeats, YWTD repeats and an O-linked sugar domain. Of the known family members, LRP5 is most closely related to LRP1. However, LRP5 has a unique organization of EGF and LDLR repeats compared to other LDLR family members and likely represents a new category in this family. LRP is expressed in rat tibia, specifically in areas of the bone that are involved in remodeling. LRP5 is a Wnt coreceptor that binds to Axin and regulates the canonical Wnt signaling pathway. LRP5 affects bone mass accrual during growth. Mutations in LRP5 cause the autosomal recessive disorder osteoporosis-pseudoglioma syndrome (OPPG). LRP5L is a related protein that exists as two isoforms produced by alternative splicing. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz